SOURCE: Masimo

Masimo

December 04, 2014 11:01 ET

Masimo iSpO2™ Pulse Oximeter Featured in Fitness Book by Tour de France Champion Greg LeMond

IRVINE, CA--(Marketwired - Dec 4, 2014) - Masimo (NASDAQ: MASI) today announced that its award-winning iSpO2™ pulse oximeter is featured in the upcoming book "The Science of Fitness: Power, Performance, and Endurance," by three-time Tour de France champion Greg LeMond and co-author interventional radiologist Dr. Mark Hom, available at Amazon.com and the Elsevier Store.

"The Science of Fitness" (by Elsevier, the world's largest scientific book publisher) explores physical performance and its relationship with oxygen and mitochondria -- the "power plants" of human cells that consume oxygen as they turn fuel (food, sugar, glycogen, and body fat) into cell energy. Arguably one of the greatest American athletes of all time, LeMond, along with Dr. Hom, tested the iSpO2 to help confirm their ideas about oxygen and to evaluate its feasibility on athletes.

"All athletes, from weekend warriors to Tour champions, get their energy from mitochondria and oxygen," said Dr. Hom. "We were able to test the iSpO2 device and found it to be very accurate, repeatable, and extremely easy to use. The iSpO2 is capable of recording and uploading graphical output of simultaneous pulse rate and oxygen saturation (SpO2) so we could analyze it later. It was small enough that we could test it on the road or when climbing stairs. Although a healthy person will not desaturate to the point of cyanosis (turning blue) even with rigorous training, we were able to see O2 saturation fluctuations in response to warm-up, intense activity, active recovery, hyperventilation, breath holding, and super-intense activity."

iSpO2, available for Android™ and Apple mobile devices, uses Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry to provide accurate, real-time oxygen saturation (SpO2), pulse rate (PR), and perfusion index (PI) readings -- ideal for anyone who desires access to accurate fitness data through their mobile iSpO2. Extremely lightweight at just 232 grams or about 0.5 pounds, iSpO2 also displays the pleth waveform and Signal IQ™ so users can visually assess their pulse rate and measurement quality to help optimize workouts and fitness levels. iSpO2 can also trend, store, and email up to 12 hours of measurement history in a global standard .CSV file format, allowing consumers to easily share data through their mobile device email application.

The iSpO2 consumer version is not intended for medical use. Please visit iSpO2.com for purchasing information.

Android is a trademark of Google Inc.

About Masimo
Masimo (NASDAQ: MASI) is the global leader in innovative noninvasive monitoring technologies that significantly improve patient care-helping solve "unsolvable" problems. In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. More than 100 independent and objective studies have shown that Masimo SET® outperforms other pulse oximetry technologies, even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced rainbow Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and Pleth Variability Index (PVI®), in addition to SpO2, pulse rate, and perfusion index (PI). Additional information about Masimo and its products may be found at www.masimo.com.

Forward-Looking Statements
This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors related to the iSpO2, including our belief in the breakthrough ability of Masimo SET® pulse oximetry to measure-through motion and low perfusion; as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.

Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care... by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO, SpMet, PVI are trademarks or registered trademarks of Masimo Corporation

Contact Information